You are here: » People » Researcher » Bandello, Francesco

Francesco Bandello

Short CV

  • Full Professor and Chairman 
  • Department of Ophthalmology 
  • University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy 
  • Member Academia Ophthalmologica Internationalis
  • Member and Vice President Academia Ophthalmologica Europea National Institute of Health(N.I.H. – U.S.A.) Peer Reviewer for grant-applications since 2006
  • Fellow of the European Leadership Development Programme (EuLDP) of the American Academy of Ophthalmology
  • Member of the Board of Directors Club Jules Gonin
  • Executive Committee Member of The Macula Society
  • President elect of the European Society of Retina Specialists (EURETINA), member of the Executive Board and chairman of the Teaching Committee of the same Society.
  • President of the Italian Society of the Retina (SIR).
  • Italian Representative European Association for Vision and Eye Research
  • Member of the International Executive Committee Michaelson Symposium
  • Member of the Subcommittee for Michaelson Award
  • Member of the Scientific Advisory Board Panel of AMD Alliance International
  • Member of the Panel Discussion (tavolo oftalmologico)of AIFA (Italian Agency for Drug)
  • Chair of the Committee for revision of the curricula for Vitreoretinal Diseases section of the International Council of Ophthalmology (ICO)       
  • Member of the Scientific Committee of Vision+ Onlus
  • Candidate for Membership of American Ophthalmological Society (AOS)      
  • Vice-president of EuroLam (European Latin American Ophthalmology)
  • Member of the “Accademia Nazionale di Medicina”
  • Member of the Steering Committee of the Osservatorio Malattie Rare (O.Ma.R)
  • Board Member of “Retinal Physician”
  • Associate Editor of the European Journal of Ophthalmology
  • Co-Editor of Developments in Ophthalmology, Karger, Basel, Switzerland
  • Editorial Board Member of Case Reports in Ophthalmology
  • Editorial Board Member of the Journal of Ocular Pharmacology and Therapeutics
  • Editorial Board member of Ophthalmologica
  • Editorial Board member of “Giornale Italiano di Vitreoretina”
  • Editorial Board member of “ISRN Ophthalmology” (International Scholarly Research Network)
  • Editorial Board member of the Springer Healthcare journal “Combination Products in Therapy”
  • Dr. Bandello served as principal investigator in several clinical trials performed following ICH/GCP and mainly concerning age-related macular degeneration and diabetic retinopathy.
  • Dr. Bandello is co-author of five books.
  • He presented well over hundreds of presentations at different meetings. These primarily relate to retinal diseases; diabetic retinopathy; age-related macular degenerations; fluorescein and indocyanine green angiographies of different retinal vascular disorders.
  • Dr. Bandello published 149 articles on Pub-Med journals mainly related to retinal diseases.

Francesco Bandello
Francesco Bandello

Research Group

Department of Ophthalmology

[more information]


University Vita-Salute Scientific Institute San Raffaele

Department of Ophthalmology

Via Olgettina, 60
20132 Milano

Phone: +39 02 2643 2648
Fax: +39 02 2643 3643



Scientifc Interest

  • Study of new therapeutical agents for the inhibition of angiogenesis and/or vasculogenesis in cases of Proliferative Diabetic Retinopathy and Age Related Macular Degeneration
  • Biomarkers in AMD
  • Correlation between systemic and ophthalmic vascular diseases
  • Medical robotics (computer- robot-assisted systems, virtual reality...) and bioengineering (image processing, process automation etc..) for the training of the operators, i.e. microsurgeons, with the aid of a computer-assisted and robotic system, the study of the retina in relation to cardiovascular disease and the improvement of the surgical techniques in terms of patient safety, precision and performance through the use of innovative technological systems


  • Retina Society
  • Macula Society
  • Club Jules Gonin
  • Academia Ophthalmologica Internationalis
  • Academia Ophthalmologica Europea
  • Euretina
  • American Academy of Ophthalmology
  • Societé Francaise d’Ophtalmologie
  • Società Oftalmologica Italiana
  • Italian Society of the Retina (SIR)
  • Accademia Nazionale di Medicina

Key Publications

  1. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.
    Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S.
    Diabetes Care. 2010 Nov;33(11):2399-405.PMID: 20980427 [PubMed - in process]
  2. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina. 2011 Oct;31(9):1841-7. PMID: 21775926 [PubMed - in process] 
  3. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
    Parodi MB, Iacono P, Kontadakis DS, Zucchiatti I, Cascavilla ML, Bandello F.
    Arch Ophthalmol. 2010 Sep;128(9):1100-3.PMID: 20837791 [PubMed - indexed for MEDLINE] 
  4. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results.
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group.
    Ophthalmology. 2011 Jul 15. [Epub ahead of print] PMID: 21764136 [PubMed - as supplied by publisher] 
  5. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
    Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group.
    Ophthalmology. 2010 Jun;117(6):1134-1146.e3. Epub 2010 Apr 24.PMID: 20417567 [PubMed - indexed for MEDLINE] 
  6. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy.
    Parodi MB, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F.
    Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4358-61. Epub 2010 Apr 7.PMID: 20375343 [PubMed - indexed for MEDLINE] 
  7. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB, Iacono P, Papayannis A, Sheth S, Bandello F.
    Arch Ophthalmol. 2010 Apr;128(4):437-42. Epub 2010 Feb 8.PMID: 20142520 [PubMed - indexed for MEDLINE] 
  8. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up.
    Veritti D, Lanzetta P, Perissin L, Bandello F.
  9. Invest Ophthalmol Vis Sci. 2009 May;50(5):2391-7. Epub 2008 Dec 30.PMID: 19117937 [PubMed - indexed for MEDLINE] 
  10. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.
    Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.
    Drugs Aging. 2008;25(3):255-68.PMID: 18331076 [PubMed - indexed for MEDLINE]
  11. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group.
    Ophthalmology. 2011 Apr;118(4):615-25. PMID: 21459215 [PubMed - indexed for MEDLINE] 

Research Groups